Guidelines recommend metformin as a first-line pharmacological treatment for the management of type 2 diabetes mellitus (T2DM). Recently, it has been proven that initial combination therapy with oral antidiabetes agents with complementary modes of action may offer more robust and durable glucose-lowering efficacy with enhanced outcomes such as renal impairment and gastrointestinal side effects compared with the traditional stepwise approach.
The complementary mechanisms of action of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and dipeptidyl peptidase-4 inhibitors (DPP4-i) suggest that the combination of empagliflozin and linagliptin may offer sustained treatment benefits in subjects with T2DM.1 In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-Specialty Panel Discussion on 7th August 2020 from 03:00 PM IST onwards. In this webinar, the expert panel…